New COVID-19 funding opportunities relevant to UC Berkeley researchers will be added as they are released by federal and state funding agencies, foundations, non-profits and industry partners. Entries are sorted in reverse chronological order. Please use the filters, sorting and search tools below to find the opportunities most useful to you. Suggest additional entries by emailing email@example.com.
If you are looking for help with large-scale state and federal proposals, or restricted and emerging opportunities, please contact the Berkeley Research Development Office (BRDO). Foundation Relations and Corporate Philanthropy provides support for your proposals to foundations and some corporate sponsors. All proposals for sponsored projects funded by government or non-profit sponsors are reviewed and authorized for submission by the Sponsored Projects Office (SPO). SPO offers an expedited review process for all COVID-19 related proposals.
|Sponsor||Grant/Award Title||Description||Funding area(s)||Amount||Sponsor Deadline||Posted on||NID||Special Notes|
|DOC Economic Development Administration (EDA)||FY 2020 SPRINT Challenge EDA-HDQ-OIE-2020-2006705||
The Department of Commerce’s (DOC) Economic Development Administration (EDA) has launched the Scaling Pandemic Resilience Through Innovation and Technology (SPRINT) Challenge, a new funding opportunity as a part of their efforts to “address the economic, health, and safety risks caused by the coronavirus pandemic.” The competition specifically aims to address regional innovation and entrepreneurship-related challenges and opportunities associated with the pandemic, including providing support for the commercialization of research and new technologies to address COVID-19 and creative efforts to promote innovation activities under current conditions.
Applicants for the challenge are expected to address “the needs and unique operating environment necessitated by the coronavirus.” Applications must also address the EDA’s Recovery and Resilience investment priority by including economic resilience and long-term recovery from natural disasters in project proposals in the context of their regional development needs. Core areas of interest include, but are not limited to, the following: 1) Biotechnology, Health Security, and Supply Chain Innovation, 2) Regional, National, and Government Connectivity, 3) Access to Capital, and 4) Innovation & Entrepreneurship. See Solicitation for further details on EDA's priority funding areas.
|Engineering; Epidemiology & Public Health; Policy, Economics & Labor||$750,000||25584|
|DOD||COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing||
The Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND) and BARDA released a request for project proposals (RPP) for prototype development to “initiate an advanced development SARS-CoV-2 medical countermeasure (MCM) prototype for clinical/non-clinical development and/or manufacturing scale-up to demonstrate the capability to support sustained large scale manufacturing,” with MCMs being either direct acting antivirals or host directed therapeutics. Search Notice ID "W911QY-20-S-0019" on beta.sam.gov for full solicitation.
|Engineering; Epidemiology & Public Health; Life Sciences||25167|
|HHS/BARDA||Operation Warp Speed Broad Agency Announcement OWS-BAA-20-01||
Operation Ward Speed (OWS) released a broad agency announcement (BAA) to solicit pre-proposals for procurement contracts, other transaction agreements, and technology investment agreements related to Plasma or Therapeutics (based on current announcement). OWS anticipates releasing future calls and solicitations under this BAA.
|Epidemiology & Public Health; Life Sciences||25166|
|Economic Development Administration (EDA)||Public Works and Economic Adjustment Assistance Programs including CARES Act Funding||
CARES Act Recovery Assistance Projects: Successful applications will enable affected communities to respond to the impacts of the coronavirus pandemic by supporting affected businesses and communities, including by providing technical assistance to retain existing and hire new employees; by providing a range of skills-training and workforce development projects to help employees compete for high-quality jobs; and by developing and implementing strategies to diversify regional economies to create jobs in new or existing industries.
|Community & Social Services; Policy, Economics & Labor||range from $150,000 to $1,000,000||25012|
|NIH-NIAID||Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)||
This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.
|Epidemiology & Public Health||Application budgets are not limited but need to reflect the actual needs of the proposed project.||24905||Limited Submission NOI due 8/26/20. NOIs accepted on a rolling basis thereafter. See campus process here https://calmessages.berkeley.edu/archives/message/77444|
|Cisco||Pandemic/COVID19 Science, Technology and Social Impact||
Pandemics have far reaching consequences that range from deaths to shutting down the economy as we have witnessed during the recent COVID19 crisis. Hence there is a need to be better prepared for such pandemics. We need to solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. The social and economic impact for the above areas is huge and some of the work can be transformative and save lives.
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health||No limitations||24906|
|Emergent Ventures||Emergent Ventures Fast Funding for COVID-19 Science||
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, the Emergent Ventures project at the Mercatus Center invites you to apply for a Fast Grant. A Fast Grant must be used solely to expedite COVID-19-related science, but the area of research is open. For this second round that opened July 12, fast grants decisions will be made within 14 days.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor||Up to $500,000||24074|
|Open Road Alliance||Charitable Grants||
Open Road is making one-time grants for discrete solutions that help projects overcome unexpected roadblocks. It is supporting organizations that are responding directly to COVID-19 and can also demonstrate how their intervention moves towards longer term adaptation and systemic/sustainable impact beyond the immediate outbreak and beyond just "flattening the curve". These grants are for mid-Implementation projects that have met roadblocks to funding, solution must be discrete with the help of one-time infusion of funds, and catalytic, with the potential to be system-changing either in design or scale.
|Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor||24739|
|University of California||UC MEXUS Supplemental COVID-19 Funding Opportunity||
Alianza UCMX has released the UC MEXUS supplemental funding opportunity for UC faculty undertaking research on COVID-19 who want to engage with Mexico. To be eligible, UC faculty must be a recipient of a coronavirus-related project award and be interested in expanding their academic engagement with faculty; graduate, professional, and undergraduate students; or researchers from a Mexican higher education institution.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor||$5,000 per PI per six month period||24662|
|NIH-NIA||NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)||
This Funding Opportunity Announcement invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19).
Applications due monthly until Feb. 2021.
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact before submitting the application.
|Epidemiology & Public Health; Life Sciences||Application budgets are not limited but need to reflect the actual needs of the proposed project.||24661|
|NIH NIMH||Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01)||
Notice of Intent to Publish a Funding Opportunity Announcement for R01 (clinical trial optional). The FOA will solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations. This FOA will utilize the R01 activity code and academic researchers will be required to partner with digital health developers and/or existing well-established digital health delivery platforms to prepare and submit applications. FOA publication expected June 2020 with applications due July 2020
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health||$750,000/yr, up to 3 yrs||24614|
|US Patent and Trade Office (USPTO)||COVID-19 Prioritized Examination Pilot Program and Patents 4 Partnerships||
The USPTO will grant qualified requests for prioritized examination without payment of certain fees associated with prioritized examination for applicants that qualify for small or micro entity status. The COVID-19 Prioritized Examination Pilot Program will accept requests for prioritized examination beginning July 13, 2020 until such time as the USPTO has accepted a total of 500 requests. The USPTO may extend the pilot program (with or without modifications) or terminate it depending on the workload and resources needed to administer the program, feedback from the public, and the effectiveness of the program.
Patents 4 Partnerships is a new online marketplace for patent owners to list patents and published applications that are available for licensing in fields that address COVID-19. The goal is to better connect in-demand intellectual property with industries interested in scaling the ideas.
|Mercatus Center||COVID-19 Response: A Call for Ideas||
The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic. See the solicitation for the specific questions of interest in the topics of restarting and reopening, institutional challenges, health and science policy, economic and regulatory policy, and monetary policy.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor||24471||Proposals will be reviewed on a rolling basis.|
|CETF and Rockefeller Philanthropy Advisors||COVID-19 Early Treatment Fund (CETF)||
The COVID-19 Early Treatment Fund (CETF) is targeting early-stage COVID infections in outpatients — as opposed to hospitalized, critically ill patients — with the aim of preventing disease progression to the severe and often fatal stage seen in 20 percent of cases. We will be funding initiatives that focus on treating outpatients to prevent hospitalization. CETF is narrowly focused on ensuring that outpatient trials for four drugs are successful (Peginterferon lambda, Favipiravir, Camostate mesylate, and Remdesivir). That means we’ll provide funding, help improve study protocols, find ways to manufacture drugs in short supply and do whatever it takes to move these medicines forward. Please share your contact information so that we can follow up to share more details and further discuss this funding opportunity. We primarily fund phase 1b/2a outpatient clinical trials that cost $1 million or less but will also consider earlier stage projects.
|Epidemiology & Public Health; Life Sciences||Up to $1M||24444|
|Economic Development Administration (EDA)||EDA CARES Act Recovery Assistance||
The Coronavirus Aid, Relief, and Economic Security (CARES) Act provides the EDA with $1.5 billion for economic development assistance programs to help communities prevent, prepare for, and respond to coronavirus. EDA CARES Act Recovery Assistance provides a wide-range of financial assistance to communities and regions as they respond to and recover from the impacts of the pandemic. This includes: 1) Planning and Technical Assistance, 2) Construction of Infrastructure and Other Economic Development Projects, 3) Innovation Grants, and 4) Capitalization and Recapitalization of Revolving Loan Funds. Check that the proposed project fits the scope with the EDA regional office; applications reviewed on rolling basis.
6/16/20 update: EDA plans to launch a new funding opportunity called the Coronavirus Entrepreneurship & Innovation Challenge which will allocate $25M to address unique innovation and entrepreneurship-related challenges & opportunities associated with the pandemic.
|Community & Social Services; Policy, Economics & Labor||24445|
|NIH NIBIB Point-of-Care Technologies Research Network (POCTRN)||Rapid Acceleration of Diagnostics (RADx): Fast-Track Program for COVID-19 Test Development and Distribution||
NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. Proposal being reviewed on a rolling basis.
|Epidemiology & Public Health; Life Sciences||Phase 0 $25,000; Phase 1 $500,000; Phase 2 tens of millions expected||24359|
|NIH-NIAID||Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 (R01 Clinical Trial Not Allowed) (PAR-20-178)||
Rapid R01 opportunity to provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. See area of interest described for the related R21 opportunity (PAR-20-177). Choose whichever funding mechanism is most appropriate (R21 or R01) for your proposed research. Typically funds available up to $500,000; must contact PO in advance if requested amount will be greater than $500k.
|Epidemiology & Public Health; Life Sciences||Typically up to $500,000||24358|
|NIH-NIAID||Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 (R21 Clinical Trial Not Allowed) (PAR-20-177)||
Rapid R21 opportunity to provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. Transmission characteristics and the associated morbidity and mortality, viral pathogenesis, host immunity, natural history, and host range are currently poorly understood. There is an urgent public health need to better understand SARS-CoV-2/COVID-19, particularly to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures and to share findings quickly and broadly. Applications will be handled on an expedited review and award basis to meet the goals of this program.
|Epidemiology & Public Health; Life Sciences||Up to $275,000||24357|
|DARPA||COVID-19 + DARPA||
4/23/20 funding update: $113 million is being reprogrammed from the Defense Health Program to DARPA's Biological Technologies Office (BTO), Defense Sciences Office (DSO), and Information Innovation Office (I2O) to address efforts relevant to the COVID-19 response. These efforts include deploying Artificial Intelligence (AI)-based models to screen for Food and Drug Administration (FDA)-approved therapeutics that may be able to treat COVID-19, running trials to test a COVID-19 RNA vaccine, developing capabilities to detect and screen environments for the airborne COVID-19 virus, and addressing supply chain vulnerabilities to develop U.S.- based production capabilities for pharmaceuticals needed to treat COVID-19, among others. Some of the activities described in the reprogramming are aligned with ongoing efforts at DARPA; it is unclear if this funding will be used to start any new efforts.
4/8/20: DARPA is encouraging researchers to submit COVID-19 related proposals through its standard Broad Agency Announcement (BAA) funding mechanism in the Biological Technologies Office or Defense Sciences Office. These BAA proposals are continuously open and reviewed.
|Behavior & Psychology; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24093|
|DOD-Army||Pre-Announcement: Potential Request for Project Proposals (RPP) for development of prototypes to combat the coronavirus||
4/23/20 Update: MTEC anticipates potential upcoming solicitations in the following areas: 1) Point-of-care diagnostics to rapidly identify infected individuals, and 2) Predictive analytics that can forecast potential hot spots and empower decision makers' response actions
4/7/20: The Army's Medical Technology Enterprise Consortium (MTEC) has posted an announcement of the possibility of RPPs to rapidly accelerate development of technology to detect exposure, prevent, contain and treat COVID-19 and future emerging threats in the following areas:
1) Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
2) Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.
3) Disease predictive modeling that provides early warning through data capture from several different streams of data to include social media and artificial intelligence (AI) parameter decision tools that would provide actionable information to medical service providers and command structures.
4) Patient monitoring, tracking, and management system for in-home or non-hospital environment patient tele-health services to include interface into the Cerner electronic health record.
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24081|
|NIH-NCATS||Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Award to Address COVID-19 Public Health Needs (NOT-TR-20-028)||
The National Center for Advancing Translational Sciences NCATS is soliciting applications for Administrative Supplements and Emergency Competitive Revisions from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients. See link for eligible program details. Applications accepted on a rolling basis through Nov. 10, 2020
|Epidemiology & Public Health; Life Sciences||24275|
|Patient-Centered Outcomes Research Institute (PCORI)||COVID-19-Related Enhancements to Existing PCORI-Funded Projects||
Rooted in its mission to help people make informed healthcare decisions and improve healthcare delivery and outcomes, PCORI is poised to support work to provide answers to the challenging COVID-19 related dilemmas facing patients, caregivers, providers, health systems, and policymakers through targeted investments in extending our Research, Engagement Awards, and Dissemination and Implementation activities. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement. Applications will be considered on a rolling basis.
|Community & Social Services; Epidemiology & Public Health||Up to $500,000||24237|
|NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Notice of Special Interest (NOSI): Availability of Administrative Supplements and Competitive Revision Supplements on COVID-19 within the Mission of NIAAA (NOT-AA-20-011)||
Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes. Applications accepted on a rolling basis
|Behavior & Psychology; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||Up to $100,000||24230|
|NIH Office of Behavioral and Social Science Research (OBSSR)||Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)||
This OBSSR NOSI seeks existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health; Policy, Economics & Labor||Up to $100,000||24204|
|Henry Wheeler Center for Emerging and Neglected Diseases (CEND)||COVID Catalyst Funding||
The Covid Catalyst fund will provide catalytic seed funding for high-risk projects, as well as catalytic bridge funding for lower risk projects that likely will be successful in attracting government funding long-term. We will be able to fund projects for 3-6 months at a time or until a major milestone is reached. High-risk ideas that turn out to be not feasible should be allowed to fail rapidly so that another approach can be taken. Once the milestone is reached, repeat funding is possible to continue towards implementation.
|Epidemiology & Public Health; Life Sciences||Up to $100K||24185|
|NIH (NCI, NCCIH, NHGRI, NIAID, NICHD, NIDDK, NIEHS, NIGMS, NIMHD, NIBIB, NCATS)||Emergency Competitive Revision to Existing NIH Awards||
The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications for Emergency Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Emergency Notice of Special Interest (NOSI) published by an IC will be allowed to apply to this FOA.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||24126|
|NIH-NCATS||Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus||
NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. This Notice announces the availability of competitive revisions for investigators and institutions funded through the NIH Microphysiological Systems (MPS) Program; or SBIR/STTR-supported investigators, provided the award involves tissue chips; or microphysiological systems programs from across NIH.
NCATS will accept the submission of applications for Competitive Revisions to active grants on a rolling basis to address only the following research areas of interest:
|Engineering; Life Sciences||24134|
|NIH-NCI||Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)||
The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer. Applications in response to this NOSI must be submitted using the following target funding opportunity announcement or subsequent reissued equivalent.
|NIH-NIBIB||Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)||
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Applications in response to this NOSI must be submitted using one of the target opportunities listed in the Notice.
|NIH-NIBIB||Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)||
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications on a rolling basis from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents:
|NIH-NIEHS||Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)||
NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Applications should be submitted using the following opportunities:
|Data Science, AI & Computing; Epidemiology & Public Health; Life Sciences||24128|
|NIH-NIMHD, NIH-NIA, NIH-NIMH||Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities||
This NOSI is soliciting research in health disparity populations that seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations. Projects must include a focus on one or more NIH-designated populations that experience health disparities in the United States, which include racial and ethnic minority groups, less privileged socioeconomic status, sexual and gender minorities and underserved rural populations.
In addition to NIMHD, The National Institute of Mental Health (NIMH) will accept and consider support for applications for supplements and revisions to NIMH projects that fall within the scope of this announcement and are relevant to the mission and strategic priorities of the NIMH. Applications to describe the epidemiology of mental disorders and symptoms related to the COVID-19 pandemic are not a high priority; applications to examine how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or worsening mental health needs where we anticipate health disparities will be most prominent will be seen as a high priority.
The National Institute on Aging (NIA) will accept applications for supplements and revisions to NIA-supported projects that fall within the scope of this announcement and are relevant to the mission and strategic priorities of the NIA. Applications are encouraged that address the specific needs and circumstances of midlife and older adults, including, but not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health; Life Sciences; Policy, Economics & Labor||24133|
|Google Cloud research credits||
Google invites applications to leverage its computing capabilities and infrastructure to study potential therapies and vaccines, track critical data, and identify new ways to combat COVID-19. Google Cloud research credits can advance your research by giving you access to computing power that will make the next big thing possible.
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24105|
|U.S.-Israel Binational Science Foundation||Call for Proposals in Joint NSF-BSF Programs Dealing with the Coronavirus Disease||
The U.S.-Israel Binational Science Foundation (BSF) is accepting applications dealing with the Coronavirus Disease in all the active NSF-BSF programs. Research projects in Biology (DEB, IOS, MCB), the Geosciences (Earth Sciences, Ocean Sciences, Atmospheric and Geospace), Engineering (CBET, ECCS, CMMI, EEC, EFMA, IIP) Materials, Physics divisions are approved for submission. The BSF is waiting for approval from other NSF units, and expects that submission to this RAPID program in more fields will be possible soon. Submission of COVID-19 related proposals to all regular NSF-BSF programs is, of course, still possible.
|Engineering; Life Sciences||24107|
|Joint European Disruptive Initiative (JEDI)||Billion Molecules against COVID-19 Grand Challenge||
The Joint European Disruptive Initiative is launching the Billion Molecules against COVID-19 Grand Challenge, with grand prizes of up to 2 million Euros. The objective: to screen billions of molecules with blocking interactions relevant to SARS-CoV-2, and fast-track the route to a therapeutic treatment. The current major health crisis has highlighted the need for strong anticipation, interdisciplinarity and massive agility. This is the first-ever DARPA-type challenge in Europe at the intersection of epidemiology, high performance computing, molecular biology and artificial intelligence. The Grand Challenge will be open to comments and input from the wider Scientific community between April 7 and April 14, after which it is expected to be open for eight weeks.
|Data Science, AI & Computing; Epidemiology & Public Health; Life Sciences||Up to 2 million Euros||24094|
|NIH-NIAID||Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)||
In this call for revisions to funded grants, NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
|NIH-NIGMS||Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-AI-20-030)||
NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
|Omidyar Network||COVID-19 Economic Response Advocacy Fund||
This fund intends to infuse funding into national, state, and local advocacy and organizing efforts aimed at passing economic stimulus to address the immediate toll of the COVID-19 pandemic on working people while reshaping economic structures to ensure they are less vulnerable in the future. The call is focused on direct advocacy efforts to achieve policy or regulatory solutions at the national, state, or local level that protect and assist working people and small businesses now and establish new precedents that improve worker power and well-being in the future; digital organizing that reconfigures campaigns that can no longer be carried out in person due to the virus; strategic communications, coordination, and narrative development efforts that bring like-minded organizations together to create a louder, more unified voice calling for policy and regulatory changes at the national, state, or local level that result in a stronger economy.
|Policy, Economics & Labor||24096|
|DOD Joint Acquisition Task Force (JATF)||COVID-19 Request for Information (RFI)||
DoD JATF is seeking input to shape its COVID-19 funding decisions focused on the accelerated ramp-up of production capacity for critical healthcare products such as masks, ventilators, test kits, and vaccines. JATF Focus Areas: 1) Combating Spread, 2) Welfare of Citizens, 3) Readiness, 4) Logistics, 5) Industrial base impacts, 6) Medical, 7) Other
|Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Policy, Economics & Labor||24075|
|DOD-Army||Army Futures Command's (AFC) Army Applications Laboratory (AAL) Request for Ideas||
The Army Futures Command’s (AFC) Army Applications Laboratory (AAL) has expressed significant interest in new technologies to support the Army’s COVID-19 response including innovative medical equipment, therapeutics, diagnostics, and vaccines. AAL has set up a webpage for organizations to schedule a brief phone call to discuss their ideas for technologies that support diagnosis, care, and the protection of healthcare providers, active duty service members, their families, and communities from COVID-19.
|Engineering; Epidemiology & Public Health; Life Sciences||24079|
|HHS-AHRQ||Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19||
AHRQ intends to publish a new funding opportunity announcement in April using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. AHRQ will look to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19; effects on quality, safety, and value of health system response to COVID-19; and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Epidemiology & Public Health; Policy, Economics & Labor||24070|
|HHS-AHRQ||Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19||
AHRQ intends to publish a new funding notice in April allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19.
|Behavior & Psychology; Community & Social Services; Epidemiology & Public Health; Policy, Economics & Labor||24069|
|HHS-BARDA||CoronaWatch/TechWatch Medical Countermeasures||
To enable a rapid-response to the COVID-19 outbreak, BARDA has repurposed its existing TechWatch program to focus on COVID-19 medical countermeasures. These CoronaWatch submissions and meetings aim to give innovators and innovative companies a government-wide platform to discuss their ideas with U.S. government experts, and seek partnership opportunities with a wide range of potential federal partners. BARDA is particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
|Engineering; Life Sciences||24072|
|NASA||Making Innovative Use of NASA Satellite Data to Address Environmental, Economic, and/or Societal Impacts of the COVID-19 pandemic||
Program Element A.28 "Rapid Response and Novel Research in Earth Science" (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 provides an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic. Potential proposals may address R&A-related topics more fundamental in underlying physical and/or biological sciences (including possible connections to socioeconomic activities) and/or ASP-related topics characterizing impacts of decisions or efforts to inform decision makers on regional-to-global levels in their responses to mitigate the impacts of the disease. While proposed studies must use NASA satellite data and information products as a primary source of information and research tools, they may also utilize remote sensing data and products from government agencies, international, or commercial sources. Studies utilizing Artificial Intelligence (AI) techniques including Machine Learning (ML) and Deep Learning (DL) are encouraged. Rolling deadline.
|Data Science, AI & Computing; Engineering||24076|
|NEH||Office of Digital Humanities COVID Response: Virtual Visits||
The Office of Digital Humanities at the National Endowment for the Humanities wants to let university instructors know that we are available to visit your classroom, library, or DH center virtually. We are offering 15-20 minute visits such as the following:
|Novartis||COVID-19 Response Fund||
In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million total over a one-year period for immediate response and recovery efforts related to the pandemic. Programs must support one or more of the three stated objectives: Strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers, establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information, or creating or enhancing new community health programs specific to the pandemic response. R&D efforts related to COVID-19 are not eligible.
|Data Science, AI & Computing; Epidemiology & Public Health||$100,000-$250,000||24068|
|Allen Institute for AI||COVID-19 Open Research Dataset Challenge (CORD-19)||
This is a call to the world's artificial intelligence experts to develop text and data mining tools that can help the medical community develop answers to high priority scientific questions using the new COVID-19 Open Research Dataset (CORD-19). CORD-19 is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses. This freely available dataset is provided to the global research community to apply recent advances in natural language processing and other AI techniques to generate new insights in support of the ongoing fight against this infectious disease.
|Data Science, AI & Computing||$1,000 per task award||24001|
|DOC-NIST||Manufacturing USA National Emergency Assistance Program||
Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.
|Community & Social Services; Epidemiology & Public Health||Up to $10,000,000||24007|
|DOE-Office of Science||RAPID REQUEST: Coronavirus Disease 2019 (COVID-19) Dear Colleague Letter||
DOE is asking for input on COVID-19 rapid research response involving DOE user facilities and infrastructure.
|Data Science, AI & Computing; Engineering; Life Sciences||24034|
|Gates Foundation, Wellcome Trust, Mastercard, CZI||COVID-19 Therapeutics Accelerator||
The Bill & Melinda Gates Foundation, along with Wellcome, Mastercard, and CZI are leading the $145 million COVID-19 Therapeutics Accelerator. The accelerator is working in tandem with the World Health Organization, national governments, business sectors and organizations to deliver end-to-end results, ‘from drug pipeline development through manufacturing and scale-up’; with a focus on minimizing the ‘financial and technical risk for academia, biotech, and pharmaceutical companies, while also ensuring that these products are accessible and affordable to people in low-resource settings’. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact firstname.lastname@example.org.
|Epidemiology & Public Health; Life Sciences||No funding limitations||24004|
|Ginkgo Bioworks||Free Access to Ginkgo Platform||
Ginkgo is offering: $25M of no-cost foundry work towards projects that can use Ginkgo’s platform to accelerate development of point of care diagnostics, vaccines, or therapeutics; as well as connection to sources of funding from private and public sources. Gingko is coordinating with entrepreneurs including Sam Altman and others on private funding efforts. Gingko also promises rapid sharing of R&D information among the community of academics and companies working on solutions. If you are currently a company or academic lab that is developing a diagnostic, drug, or vaccine and are interested in leveraging Ginkgo’s infrastructure at no cost email email@example.com.
|Data Science, AI & Computing; Epidemiology & Public Health; Life Sciences||In-Kind||24008|
|HHS-BARDA||Broad Agency Announcement||
Biomedical Advanced Research and Development Authority (BARDA) is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003). COVID-19 response related Areas of Interest includes: Diagnostic assay for human coronavirus using existing FDA-cleared platforms; Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), COVID-19 Vaccine, COVID-19 Therapeutics, Immunomodulators or therapeutics targeting lung repair, Pre-exposure and post-exposure prophylaxis, Respiratory protective devices, Ventilators, and Advanced Manufacturing Technologies.
|Engineering; Life Sciences||24030|
|HHS-BARDA||BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement: Molecular Diagnostics and Nonclinical Assays||
Biomedical Advanced Research and Development Authority (BARDA) is looking for: Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform, Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease, Nonclinical model development and screening for SARS-CoV-2 virus, Alternate vaccine delivery/administration and adjuvants, and Advanced manufacturing technologies. Rolling deadline.
|Engineering; Life Sciences||24031|
|NIH-NIA||Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)||
NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.
|Behavior & Psychology; Epidemiology & Public Health||24006|
|NSF||Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)||
The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.
|Data Science, AI & Computing||24033|
|NSF||Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)||
National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
|Behavior & Psychology; Community & Social Services; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Humanities; Life Sciences; Policy, Economics & Labor; Instruction||24032|
|OSTP DOE IBM||COVID-19 High Performance Computing Consortium||
The COVID-19 High Performance Computing Consortium helps aggregate computing capabilities from the world's most powerful and advanced computers to help COVID-19 researchers execute complex computational research programs to help fight the virus. Researchers seeking to access the Consortium’s resources should submit a simple project proposal that will be reviewed for potential impact, computational feasibility, overall resource requirements and timeline.
|Behavior & Psychology; Data Science, AI & Computing; Engineering; Epidemiology & Public Health; Life Sciences||24035|
|Pulitzer Center on Crisis Reporting||Coronavirus News Collaboration Challenge||
The Pulitzer Center on Crisis Reporting, a non-profit organization that supports independent global journalism, is seeking proposals that develop innovative approaches to reporting on the novel coronavirus crisis using collaboration among journalists and newsrooms across state lines or national borders. This opportunity is open to all newsrooms and independent journalists in the United States and abroad.
|Community & Social Services; Policy, Economics & Labor||No funding limitations||24011|
|NIH-NCATS||Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)||
NCATS is particularly interested in projects that repurpose existing drugs or biologics that have already begun or completed a Phase I clinical trial. Deadline: Varies by program, see the NOSI.
|NIH-NCATS||Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need (NOT-TR-20-011)||
NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. Deadline: Varies by program, see the NOSI.
If your proposed research on SARS-CoV-2/COVID-2019 is within the scope of your current NIAID grant, an administrative supplement is your best option to obtain additional funding.
|NIH-NIAID||Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)||
NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
|NIH-NIAID & NIGMS||Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (NOT-AI-20-030)||
NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens. Deadline: 2/6/2021 4/7/2020. NOTE: As of 4/8/2020, this NOSI (NOT-AI-20-030), will be rescinded (NOT-AI-20-040) and replaced by NOT-AI-20-034 for NIAID competitive revisions and NOT-GM-20-025 for NIGMS competitive revisions.
|NIH-NIDA||Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)||
NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders